This active metabolite irreversibly blocks the P2Y12
Ticlopidine is used to reduce the risk of stroke in people who have had a stroke or have had warning signs of a stroke and who cannot be treated with aspirin
The most frequent side
In Vitro Activity
Unipar is a Brazilian company organized in 1969
When ticlopidine and clopidogrel were first brought to the market, ticlodipine in 1978 and clopidogrel in 1998, the mechanism of action of these two major antithrombotic drugs was not fully understood
Its maximum antiplatelet action is at a dosage of 500 mg/day, it reaches maximum effect at 3 to 5 days, and its effects last the lifetime of the platelets
The drug has no significant in-vitro activity
Since 75 mg/day clopidogrel was confirmed to be as effective as aspirin, 75 mg/day ticlopidine may provide the effect achieved by 100 mg/day aspirin or 75 mg
Ticlopidine is used to lessen the chance of having a stroke
1016/0049-3848(83)90359-6 No abstract available
v
Thromb Haemost 1990; 64 (1): 105–155
Ticlopidine also can cause neutropenia, which is an abnormally small number of mature white blood cells (WBCs)
Their mode of action has not been defined, but it appears that they require conversion to as yet unidentified metabolites that are noncompetitive antagonists of the platelet ADP receptor
Ticlopidine - action
Most dangerous - agranulocytosis, aplastic anemia, intracerebral bleeding, neutropenia
Thienopyridines are a class of selective, irreversible [1] ADP receptor / P2Y12 inhibitors used for their anti- platelet activity
During ticlopidine treatment in an 18-year-old boy, ciclosporin blood concentrations fell from about 200 to 80 mg/l and rose when ticlopidine was withdrawn; the same pattern occurred during a later rechallenge [42]
Rationale: Ticlopidine is an antiplatelet agent that is used for the prevention of thrombotic stroke